Differential MIR-21 Expression in Plasma From Mesenteric Versus Peripheral Veins

An Observational Study of Disease-free Survival in Surgically Resected Colon Cancer Patients

Mariano Monzo, MD, PhD, Francisco Martinez-Rodenas, MD, PhD, Isabel Moreno, MD, PhD, Alfonso Navarro, PhD, Sandra Santasusagna, MS, Ismael Macias, MD, Carmen Muñoz, MS, Rut Tejero, PhD, and Raquel Hernández, MD

Abstract: Findings on the role of plasma miR-21 expression in colorectal cancer are contradictory. Before reaching a peripheral vein (PV), microRNAs released by the tumor are dispersed throughout the body. We hypothesized that blood drawn from the mesenteric vein (MV) near the site of the primary tumor could provide more homogeneous information than blood drawn from the PV.

We have analyzed miR-21 expression in matched samples of tumor tissue, normal tissue, MV plasma, and PV plasma in 57 surgically resected patients with colon cancer and correlated our findings with clinical characteristics and disease-free survival (DFS).

miR-21 expression was higher in MV than PV plasma \( (P = 0.014) \) and in tumor than in normal tissue \( (P < 0.001) \). Patients with high levels of miR-21 in MV plasma had shorter DFS \( (P = 0.05) \) than those with low levels, and those with high levels in both MV and PV plasma had shorter DFS than all other patients \( (P = 0.01) \).

Our findings suggest that the primary tumor in colon cancer releases high concentrations of miR-21 in the MV but that these concentrations are later diluted in the circulatory system. MV expression of miR-21 may be a stronger prognostic marker than PV expression.

(Medicine 94(1):e145)

Abbreviations: CRC = colorectal cancer, CT = computed tomography, DFS = disease-free survival, miRNA = microRNA, MV = mesenteric vein, PV = peripheral vein.

INTRODUCTION

Colorectal cancer (CRC) is the third most common type of cancer and the second cause of cancer death worldwide.\(^1\) The main prognostic factor for relapse and survival in CRC is disease stage, and patients with stage III disease have a higher risk of relapse than those with stage II. Surgery is the standard treatment for stage I to III, and adjuvant treatment has been shown to be effective in stage III but less so in stage II.\(^2\) Prognostic and predictive biomarkers can provide a useful tool for selecting treatment and improving outcome in these patients. The analysis of biomarkers in the plasma or serum of CRC patients is a noninvasive yet effective way to determine prognosis, detect occult tumors, and monitor treatment.

MicroRNAs (miRNAs), noncoding RNAs that play a key role in the regulation of mRNA expression, are promising diagnostic and prognostic biomarkers in several cancers.\(^3\) Numerous studies have shown that miRNAs are aberrantly expressed during tumor development and can act either as oncogenes or tumor suppressors.\(^4,5\) The specific mechanism whereby tumor cells release miRNAs into the blood is not completely understood. Recent studies have shown that exosomes and microvesicles can act as miRNA transporters,\(^6–8\) whereas other studies have found that miRNAs circulate freely in blood by binding to the AGO-2 protein complex, which prevents the digestion of RNase in plasma.\(^9\)

miR-21 was the first tumor-related miRNA to be identified, detected in the serum of a patient with B-cell lymphoma.\(^10\) Since then, miR-21 has been widely studied in tumor, plasma, and serum samples, both in CRC and in other tumors, where it controls carcinogenesis by targeting different genes, including TPML,\(^11\) PDCD4,\(^12,13\) PTEN,\(^14\) and BTG2.\(^15\) In hepatocellular carcinoma\(^16\) and non–small-cell lung cancer,\(^17\) plasma and serum levels of miR-21 have been identified as reliable biomarkers for both diagnosis and prognosis. In addition, postoperative levels of miR-21 were lower than baseline levels in both gastric cancer\(^18\) and squamous cell carcinoma of the esophagus.\(^19\)

In CRC, some studies have identified miR-21 in serum\(^20,21\) or plasma\(^22–23\) as a useful diagnostic and prognostic biomarker. However, in other studies, miR-21 expression was not detected in the peripheral blood of CRC patients, although other miRNAs, including miR-17–3– miR-92,\(^24\) miR-29a,\(^25\) miR92a,\(^26\) and miR-221,\(^27\) were identified as circulating tumor biomarkers. These contradictory findings may be due to various causes, including differences in patient characteristics, internal controls, and cutoff values. Importantly, all previous studies of circulating miR-21 in CRC have consistently obtained circulating miRNAs from an area far from the primary tumor, generally from a peripheral vein (PV) located in the forearm. However,
before reaching the PV of the forearm, the miRNAs released by the tumor are diluted and dispersed in other parts of the body, which may explain the inconsistency between miRNA expression levels in the tumor itself and those detected in peripheral blood.

In CRC, venous return occurs through the superior mesenteric vein (MV) if the tumor is located in the right colon, through the inferior MV if the tumor is located in the left colon, and through the iliac veins if the tumor is located in the middle or lower third rectum. Therefore, we can hypothesize that in colon cancer, blood samples drawn from the MV near the site of the primary tumor can provide more homogeneous and effective information than blood drawn from the PV of the forearm. To test this hypothesis, we have analyzed miR-21 expression in paired samples of tumor tissue, normal tissue, plasma obtained by blood drawn from the MV, and plasma obtained by blood drawn from the PV in 57 surgically resected patients with colon cancer and correlated our findings with the clinical characteristics and disease-free survival (DFS) of these patients.

METHODS

Eligibility and Patient Evaluation

From August 2009 to August 2013, samples were obtained from 57 patients with stage I to IV colon cancer who underwent surgical resection at the Municipal Hospital of Badalona. Approval for the study was obtained from the institutional review board of the hospital, and signed informed consent was obtained from all patients and controls in accordance with the Declaration of Helsinki.

All 57 patients underwent a complete history and physical examination including routine hematological and biochemical analyses, chest radiographs, and computed tomography (CT) of the thorax and abdomen. Target lesions detected by abdominal ultrasound were also assessed by CT or magnetic resonance imaging.

Samples

For all 57 patients, we obtained tumor tissue, paired normal tissue, MV blood, and PV blood. Normal tissue was obtained from the area of the colon farthest from the tumor. Both tumor and normal tissue samples were analyzed and confirmed by a pathologist and frozen at −80°C for further use.

On the day of surgery, 5 mL of blood was drawn from the PV and stored in heparinized tubes. During surgery, vacuum blood samples were drawn from either the superior or the inferior MV, with vascular ligation before tumor resection, an additional 5 mL of blood was drawn from the MV near the site of the primary tumor. Both tumor and normal tissue samples were analyzed and confirmed by a pathologist and frozen at −80°C for further use.

RNA Extraction and miRNA Quantification

Total RNA was extracted from fresh tissue and paired normal tissue and from PV plasma and paired MV plasma using miRNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. miRNA detection was performed using commercial assays (TaqMan MicroRNA assays, Life Technologies, Grand Island, NY, USA) for miR-21, in the 7500 Sequence Detection System (Life Technologies). The appropriate negative controls (non-template control) were also run in each reaction. All reactions were performed in duplicate. Relative quantification was calculated using the formula 2−ΔΔCt. Normalization was performed with miR-191.

Statistical Analyses

Differences between ≥2 groups were calculated using the Mann–Whitney U test or the Kruskal–Wallis test as appropriate. miR-21 expression levels were dichotomized according to the fixed threshold method using the maxstat package of R to determine the optimal cutoff that best discriminated between different groups of patients for DFS. Fifty-two patients were evaluable for DFS; the 5 stage IV patients in whom only the primary tumor—but not the metastasis—was removed were not included in the analysis of DFS. DFS was calculated from the date of surgery to the date of death, relapse, or last follow-up. The univariate analysis of DFS was performed with the Kaplan–Meier method and compared using the log-rank test. All statistical analyses were performed with SPSS 14.0 (SPSS Inc, Chicago, IL) and R 2.6.0 Software (Vienna, AU). Statistical significance was set at P ≤ 0.05.

RESULTS

miR-21 Expression in Plasma and Tissue

Median miR-21 expression (fold change) was 0.2874 in MV plasma, 0.1805 in PV plasma, and 0.0201 in plasma from healthy controls. Median miR-21 expression in tumor and normal tissue was 0.3907 and 0.1733, respectively. miR-21 expression was significantly higher in MV plasma compared with PV plasma (P = 0.005) (Figure 1A). miR-21 expression was also significantly higher in tumor than in normal tissue (P < 0.001) (Figure 1A).

Patient Characteristics and miR-21 Expression

Table 1 shows the clinicopathologic characteristics of the 57 patients included in the study. Median age was 70 years. Thirty-eight patients were males and 29 females. At diagnosis, 35 patients were having stage I to II of cancer, 15 stage III, and 7 stage IV. All patients underwent surgical resection; in 2 of the 7 stage IV patients, both the primary tumor and the metastasis were removed. Twenty-eight patients received adjuvant therapy with fluoropyrimidines.

MV miR-21 levels correlated positively with tumor size (P = 0.04) and showed a trend toward correlation with carcinoma embryonic antigen levels (P = 0.08). Among patients with stage I to II disease, miR-21 levels were higher in MV plasma than in PV plasma (P = 0.001), whereas no significant differences were observed among patients with stage III to IV disease (Figure 1B). A highly significant association was observed between MV miR-21 levels and the anatomic location of the tumor (P = 0.003), whereas the association with PV miR-21 levels was less significant (P = 0.01) (Table 1, Figure 1C).

miR-21 Expression and Metastases

Of the 13 patients who developed metastases during the course of the disease, 8 had metastases in areas drained by the MV of the colon: 4 peritoneal metastases, 2 liver metastases, and 2 anastomotic. Of these 8 patients, 7 had higher miR-21 expression levels in MV plasma than in PV plasma (P = 0.02) (Table 2, Figure 1D).
miR-21 Expression and DFS

Fifty-two patients were evaluable for DFS. Median DFS was not reached among the 8 patients with low levels of miR-21 in MV plasma, compared with 32.2 months (95% confidence interval [CI] 27.9–37.5) for the 44 patients with high levels of miR-21 (P = 0.05; Figure 2A). Median DFS was 38.1 months (95% CI 32.1–44.2) for the 24 patients with low levels of PV miR-21 and 30.1 months (95% CI 23.5–36.7) for the 28 patients with high levels (P = 0.07; Figure 2B).

To further evaluate whether the levels of miR-21 in both MV and PV plasma could have a combinatory effect on DFS, we classified patients in 3 groups: those with high miR-21 levels in both MV and PV plasma, those with low levels in both MV and PV plasma, and those with other combinations of miR-21 levels. Median DFS for the 8 patients with low MV and PV miR-21 was not reached, compared with 29.1 months (95% CI 22.2–35.9) for the 26 patients with high MV and PV miR-21 and 31.2 months (95% CI 24.9–37.5) for the remaining 18 patients (P = 0.03; Figure 2C). Based on these findings, we then compared DFS in the 26 patients with high miR-21 expression in both MV and PV plasma with all other patients. Median DFS was 29.1 months (95% CI 22.2–35.9) for these 26 patients versus 40 months (95% CI 34.8–45.2) for the remaining patients (P = 0.01; Figure 2D).

**DISCUSSION**

The main cause of death in patients with solid tumors is the development of metastases. The analysis of plasma and serum from cancer patients can help identify reliable biomarkers to predict relapse and metastasis in these patients. Recent findings suggest that the primary tumor can release proteins and miRNAs into the blood, which will organize a microenvironment known as a premetastatic niche in an area far from the primary tumor.28,29 Logically, the veins that are nearest the primary tumor would be most likely to contain the greatest concentration of these proteins and miRNAs.

The present study shows that miR-21 expression levels are significantly higher in MV plasma than in PV plasma. This finding suggests that the primary tumor in colon cancer releases high concentrations of miR-21 in the MV, but that these concentrations are later diluted in the circulatory system. This would explain why in other studies, only approximately 30% of
### TABLE 1. Patient Characteristics

| Characteristics                  | Plasma From Mesenteric Vein | Plasma From Peripheral Vein |
|----------------------------------|-----------------------------|-----------------------------|
| **N (%)**, N = 57                |                             |                             |
| **P value for Association With miR-21 Expression** |                             |                             |
| **Sex**                          |                             |                             |
| Male                             | 34 (60)                     | 23 (40)                     |
| Female                           | 23 (40)                     | 34 (60)                     |
| **Median age, y**                | 70                          | 70                          |
| **CEA levels**                   |                             |                             |
| \(\leq 5\)                      | 38 (67)                     | 19 (33)                     |
| \(> 5\)                         |                             |                             |
| **C 19.9 levels**                |                             |                             |
| \(\leq 37\)                     | 50 (88)                     | 7 (12)                      |
| \(> 37\)                        |                             |                             |
| **Tumor location**               |                             |                             |
| Ascending colon                  | 17 (30)                     | 8 (14)                      |
| Transverse colon                 | 8 (14)                      | 7 (12)                      |
| Descending colon                 | 7 (12)                      |                             |
| Sigmoid colon                    | 25 (44)                     |                             |
| **Tumor size, cm**               |                             |                             |
| \(> 5\)                         | 14 (24)                     | 0.05                        |
| \(\leq 5\)                      | 42 (74)                     | 0.2                         |
| **Histological type**            |                             |                             |
| Well differentiated              | 50 (88)                     | 0.5                         |
| Poorly differentiated            | 7 (12)                      | 0.3                         |
| **Preexistent polyp**            |                             |                             |
| Absent                           | 44 (77)                     | 0.5                         |
| Present                          | 13 (23)                     | 0.2                         |
| **Perilymphatic invasion**       |                             |                             |
| Absent                           | 52 (91)                     | 0.1                         |
| Present                          | 4 (7)                       | 0.1                         |
| unknown                          | 1 (2)                       |                             |
| **TNM stage**                    |                             |                             |
| I–II                             | 35 (62)                     | 0.8                         |
| III                              | 15 (26)                     | 0.6                         |
| IV                               | 7 (12)                      |                             |
| **Adjuvant treatment**           |                             |                             |
| Fluoropyrimidines                | 28 (50)                     | 0.8                         |
| Palliative                       | 5 (8)                       | 0.8                         |
| None                             | 24 (42)                     |                             |

CEA = carcinoma embryonic antigen, TNM = tumor, nodule, metastasis.

### TABLE 2. Characteristics of 8 Patients Who Developed Locoregional Metastases

| Patient | miR-21 Expression in PV Plasma | miR-21 Expression in MV Plasma | Disease Stage | Tumor location | Type of Metastasis |
|---------|--------------------------------|--------------------------------|---------------|----------------|-------------------|
| 1       | 0.180685                       | -0.027026                       | IIIC          | Sigmoid colon  | Anastomotic leakage |
| 2       | -0.186873                      | 0.036793                        | IIIB          | Sigmoid colon  | Liver              |
| 3       | -0.073384                      | 0.108137                        | IIIC          | Sigmoid colon  | Peritoneal         |
| 4       | -0.112819                      | 0.149980                        | IIA           | Ascending colon| Anastomotic leakage |
| 5       | 0.117168                       | 0.462750                        | IIIB          | Transverse colon| Peritoneal         |
| 6       | 0.197543                       | 0.511818                        | IIIC          | Transverse colon| Liver              |
| 7       | 0.180384                       | 0.759566                        | IIIC          | Transverse colon| Peritoneal         |
| 8       | 0.625005                       | 1.499196                        | IIIB          | Transverse colon| Peritoneal         |

MV = mesenteric vein, PV = peripheral vein.
miRNAs detected in PV plasma or serum mirrored those found in the primary tumor.30 Furthermore, miR-21 levels in MV plasma showed a trend toward correlation with CEA5 levels. In fact, previous studies have shown that in patients with CRC, CEA5 levels are higher in the MV than in the PV.31,32 A previous study with a large cohort of patients20 found a correlation between tumor size and miR-21 expression in PV plasma; our findings are similar, but we observed this correlation only in MV plasma. We also found an association between the anatomic location of the tumor and miR-21 expression in both MV and PV plasma, although miR-21 expression was higher in MV than in PV plasma. In addition, recent studies in CRC patients have observed circulating tumor cells in blood obtained from MVs and from hepatic veins.33 Taken together with these previous results, our findings indicate that veins near the tumor are the best source of biomarkers.

Similar to our findings, previous studies found no association between miR-21 expression and tumor stage, which may have been due to the use of different internal controls in these studies.21 However, among patients with stage I to II disease, we did observe a significant overexpression of miR-21 in MV plasma compared with PV plasma, which would confirm previous reports30,21 that miR-21 is overexpressed in the early stages of tumor development.

At 4 years of follow-up, patients with high miR-21 levels in MV plasma had a significantly worse prognosis than those with low levels; in contrast, no differences were observed according to miR-21 expression in PV plasma. Interestingly, however, patients with high miR-21 expression in both MV and PV plasma also had a significantly shorter DFS than those with low levels in either MV or PV plasma. We can speculate that whether initial MV and PV levels are high; PV levels that remain high throughout follow-up may well be used to identify patients with a high risk of relapse.

Interestingly, the 8 patients who relapsed and developed metastases in areas drained by the MV of the colon—the liver and intestines—had higher levels of MV miR-21 than PV miR-21. In contrast, metastases in areas not drained by the MV of the colon—such as the lung—were not associated with miR-21 expression levels. In fact, miR-21 has been associated with hepatocellular tumors in several studies, which have shown that miR-21 targets several genes—such as MAP2K3,34 PDCD4,35

FIGURE 2. DFS according to miR-21 levels (fold change). (A) DFS according to miR-21 expression in plasma from the MV. (B) DFS according to miR-21 expression in plasma from the PV. (C) DFS in patients with high miR-21 expression in both MV and PV plasma compared with those with low expression in both the MV and the PV and those with other combinations. (D) DFS in patients with high miR-21 expression in both MV and PV plasma compared with all other patients. DFS = disease-free survival, MV = mesenteric vein, PV = peripheral vein.
and PTEN—leading to the development of hepatocellular carcinomas. In a large cohort of patients with hepatocellular carcinomas, array analysis identified a panel of 7 miRNAs (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, and miR-801), wherein miR-21 expression levels were able to distinguish patients from healthy controls.

It has recently been reported that miRNAs released by the primary tumor can play a key role in preparing the premetastatic niche. miR-21 and miR-29a are released by tumor cells through exosomes, which bind to the Toll-like receptors of immune cells. The activation of the Toll-like receptors leads to the release of tumor necrosis factor-α and interleukin-6, which in turn prepare the extracellular environment for tumor growth and dissemination. Our findings suggest that the miRNAs released in the MV may be retained in areas near the primary tumor (liver and intestines), where they could work to build the premetastatic niche. To validate these findings, however, further research on other miRNAs associated with colon cancer should compare expression levels in MV and PV plasma and examine the potential association between MV plasma expression and locoregional metastases. The findings of the present study will hopefully act as a springboard to strengthen collaboration among surgeons, medical oncologists, and molecular biologists with the aim of improving outcome in colon cancer patients.

REFERENCES

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–2029.
3. Yang X, Lee Y, Fan H, et al. Identification of common microRNA-miRNA regulatory biomodules in human epithelial cancers. Chin Sci Bull. 2010;55:3576–3589.
4. Schwarzenbach H, Nishida N, Calin GA, et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11:145–156.
5. Allegra A, Alonci A, Campo S, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41:1897–1912.
6. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol. 2009;11:1143–1149.
7. Gibbings DJ, Ciudao C, Erhardt M, et al. Multivesicular bodies in plasma are a potential diagnostic marker of colorectal cancer. Cancer Res. 2012;72:3200–3205.
8. Roberts CT Jr, Kurre P. Vesicle trafficking and RNA transfer add complexity and connectivity to cell-cell communication. Cancer Res. 2013;73:3200–3205.
9. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108:5003–5008.
10. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–675.
11. Zhu S, Si ML, Wu H, et al. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007;282:14328–14336.
12. Chang KH, Miller N, Kheirelseid EA, et al. MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur J Surg Oncol. 2011;37:597–603.
13. Qi L, Bart J, Tan LP, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9:163. doi:10.1186/1471-2407-9-163.
14. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–658.
15. Coppola V, Musumeci M, Patrizii M, et al. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. Oncogene. 2013;32:1843–1853.
16. Bhirer V, Waidmann O, Friedrich-Rust M, et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One. 2011;6:e26971.
17. Wei J, Gao W, Zhu CJ, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small lung cancer. Chin J Cancer. 2011;30:407–414.
18. Ma GJ, Gu RM, Zhu M, et al. Plasma post-operative miR-21 expression in the prognosis of gastric cancers. Asian Pac J Cancer Prev. 2013;14:7551–7554.
19. Komatsu S, Ichikawa D, Takeshita H, et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer. 2011;105:104–111.
20. Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105:849–859.
21. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138:1659–1666.
22. Kanaan Z, Rai SN, Eichenberger MR, et al. Plasma miR-21: A potential diagnostic marker of colorectal cancer. Ann Surg. 2012;256:544–551.
23. Wang Y, Gao X, Wei F, et al. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene. 2014;533:389–397.
24. Ng AD, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58:1375–1381.
25. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118–126.
26. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012;36:e61–e67.
27. Pu XX, Huang GL, Gao HQ, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25:1674–1680.
28. Scenejay N, Smyth MJ, Moll F. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 2013;32:449–464.
29. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–252.
30. Pigati L, Yaddanapudi SC, Iyengar R, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One. 2010;5:e13515.
31. Ivanovics IG, Fernandes LC, Saad SS, et al. Peripheral and mesenteric serum levels of CEA and cytokeratins, staging and histopathological variables in colorectal adenocarcinoma. World J Gastroenterol. 2008;14:6699–6703.
32. Rezende Junior HC, Palma RT, Toloi GC, et al. Carcinoembryonic antigen levels in the peripheral and mesenteric venous blood of patients with rectal carcinoma. Arch Gastroenterol. 2013;50:264–269.
33. Steinert G, Scholch S, Niemietz T, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. *Cancer Res.* 2014;74:1694–1704.

34. Xu G, Zhang Y, Wei J, et al. MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. *BMC Cancer.* 2013;13:469. doi: 10.1186/1471-2407-13-469.

35. Zhu Q, Wang Z, Hu Y, et al. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. *Oncol Rep.* 2012;27:1660–1668.

36. Damania P, Sen B, Dar SB, et al. Hepatitis B Virus Induces Cell Proliferation via HBx-Induced microRNA-21 in Hepatocellular Carcinoma by Targeting Programmed Cell Death Protein4 (PDCD4) and Phosphatase and Tensin Homologue (PTEN). *PLoS One.* 2014;9:e91745.

37. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. *J Clin Oncol.* 2011;29:4781–4788.

38. Ghasemi R, Grassadonia A, Tinari N, et al. Tumor-derived microvesicles: the metastasomes. *Med Hypotheses.* 2013;80:75–82.

39. Squadrito ML, Etzrodt M, De Palma M, et al. MicroRNA-mediated control of macrophages and its implications for cancer. *Trends Immunol.* 2013;34:350–359.

40. Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. *Proc Natl Acad Sci U S A.* 2012;109:E2110–2116.